作者：
T H T,Nguyen [1]
;
M-S,Mouksassi [2]
;
N,Holford [3]
;
N,Al-Huniti [4]
;
I,Freedman [5]
;
A C,Hooker [6]
;
J,John [7]
;
M O,Karlsson [6]
;
D R,Mould [8]
;
J J,Pérez Ruixo [9]
;
E L,Plan [10]
;
R,Savic [11]
;
J G C,van Hasselt [12]
;
B,Weber [13]
;
C,Zhou [14]
;
E,Comets [1]
;
F,Mentré [15]
;
Model Evaluation Group of the International Society of Pharmacometrics (ISoP) Best Practice Committee [1]
作者单位：
INSERM, IAME, UMR 1137, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
[1]
Certara Strategic Consulting, Montréal, Canada.
[2]
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.
[3]
Quantitative Clinical Pharmacology, AstraZeneca, Waltham, Massachusetts, USA.
[4]
Dr Immanuel Freedman Inc., Harleysville, Pennsylvania, USA.
[5]
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
[6]
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC, USA.
[7]
Projections Research Inc., Phoenixville, Pennsylvania, USA.
[8]
The Janssen Pharmaceutical Companies of Johnson & Johnson, Belgium.
[9]
Pharmetheus, Uppsala, Sweden.
[10]
Department of Bioengineering and Therapeutic Sciences, University of California - San Francisco, San Francisco, California, USA.
[11]
Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
[12]
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
[13]
Genentech, San Francisco, California, USA.
[14]
INSERM CIC 1414, Rennes, France, University Rennes-1, Rennes, France.
[15]
DOI
10.1002/psp4.12161
PMID
27884052
发布时间
2024-05-24
换一批
换一批
